A Non-Blinded Study Demonstrating the Effectiveness and Safety of Azilect Alone or in Combination Therapy in Parkinson's Disease

• Status: Completed
• Trial end date: 2007-07-01
• Target enrollment: 0
• Participant gender: All

Summary

Patients with Parkinson's Disease (PD) will be divided into 2 groups at each study center at their first visit based on the drugs they are taking for their PD:

• Group 1 Patients using Azilect and no other therapy.

• Group 2 Azilect in combination with other medications like Levodopa, Mirapex, or Requip.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Teva Neuroscience, Inc.
• Treatments: Levodopa; Pramipexole; Rasagiline; Ropinirole

Criteria

Inclusion Criteria:

1. Idiopathic Parkinson's disease. Diagnosis previously confirmed by the presence of bradykinesia and by at least one additional cardinal sign (i.e., resting tremor, rigidity), without other known or suspected cause of parkinsonism.

2. Requiring therapy for PD symptom control

• Azilect monotherapy.

• Azilect as adjunct therapy..

Exclusion Criteria:

1. Patients previously exposed to Azilect

2. Patients with pheochromocytoma

3. Concomitant MAO inhibitors or medications contraindicated for use with MAO inhibitors are not allowed.